Sunshine Biopharma (SBFM) Change in Accured Expenses (2012 - 2026)
Sunshine Biopharma's (SBFM) quarterly Change in Accured Expenses came in at -$455836.0 in Q1 2026, up 6.21% YoY from -$429190.5 in Q1 2025, and up 19.33% on a QoQ basis from -$565040.0 in Q4 2025.
Sunshine Biopharma (SBFM) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 15 years of Change in Accured Expenses data on file, last reported at -$455836.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 6.21% year-over-year to -$455836.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$159783.0 (down 107.25% YoY) and the FY2025 annual result came in at -$189956.0, down 104.77% from the prior year.
- Change in Accured Expenses climbed to -$455836.0 in Q1 2026, from -$565040.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $1.8 million in Q4 2024 to a low of -$1.0 million in Q2 2023.
- A 5-year average of $113266.8 and a median of -$73661.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 2084.3% — and 2023, when it sank 10997.79%.
- Tracing SBFM's Change in Accured Expenses over 5 years: stood at -$485554.0 in 2022, then plunged by 59.85% to -$776161.0 in 2023, then surged by 326.07% to $1.8 million in 2024, then slumped by 132.2% to -$565040.0 in 2025, then grew by 19.33% to -$455836.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$455836.0 (Q1 2026), -$565040.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sunshine Biopharma | 1.58 Mn | -12.17 Mn | 2.43 Mn | -156,687.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -156,687.00 |
| Jun 30, 2026 | -156,687.00 |
| Mar 31, 2026 | -455,836.00 |
| Mar 31, 2026 | -455,836.00 |
| Dec 31, 2025 | -565,040.00 |
| Dec 31, 2025 | -565,040.00 |
| Sep 30, 2025 | 1.22 Mn |
| Sep 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | -363,693.00 |
| Jun 30, 2025 | -363,693.00 |
| Mar 31, 2025 | -486,009.00 |
| Mar 31, 2025 | -486,009.00 |
| Dec 31, 2024 | 1.75 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | -565,724.00 |
| Sep 30, 2024 | -565,724.00 |
| Jun 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.29 Mn |